IDEXX LABORATORIES INC /DE APIC, Share-based Payment Arrangement, Increase for Cost Recognition
IDEXX LABORATORIES INC /DE (IDXX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $16.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $16.09M, a 8.31% increase year-over-year.
- IDEXX LABORATORIES INC /DE apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $16.34M, a 11.80% increase year-over-year.
- IDEXX LABORATORIES INC /DE apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $14.43M, a 9.33% decline year-over-year.
- IDEXX LABORATORIES INC /DE apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $14.85M, a 5.50% decline year-over-year.
- IDEXX LABORATORIES INC /DE apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $60.01M, a 0.47% decline from fiscal 2024.
- IDEXX LABORATORIES INC /DE apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $60.30M, a 0.93% increase from fiscal 2023.
- IDEXX LABORATORIES INC /DE apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $59.74M, a 20.03% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $49.77M, a 31.82% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.09M 10-Q · filed 2026-08-04 | $32.43M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $16.34M 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $60.01M 10-K · filed 2026-02-20 | |||
| 2025-09-30 | $14.43M 10-Q · filed 2025-11-03 | $29.29M derived: sum of 2 quarters · filed 2026-08-04 | $43.90M derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-06-30 | $14.85M 10-Q · filed 2026-08-04 | $29.47M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $14.62M 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $60.30M 10-K · filed 2026-02-20 | |||
| 2024-09-30 | $15.92M 10-Q · filed 2025-11-03 | $31.64M derived: sum of 2 quarters · filed 2025-11-03 | $46.04M derived: sum of 3 quarters · filed 2025-11-03 | |
| 2024-06-30 | $15.72M 10-Q · filed 2025-11-03 | $30.12M derived: sum of 2 quarters · filed 2025-11-03 | ||
| 2024-03-31 | $14.40M 10-Q · filed 2025-11-03 | |||
| 2023-12-31 | $59.74M 10-K · filed 2026-02-20 | |||
| 2023-09-30 | $15.22M 10-Q · filed 2024-10-31 | $30.59M derived: sum of 2 quarters · filed 2024-10-31 | $44.52M derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | $15.36M 10-Q · filed 2024-10-31 | $29.29M derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $13.93M 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | $49.77M 10-K · filed 2025-02-21 | |||
| 2022-09-30 | $12.95M 10-Q · filed 2023-11-01 | $25.32M derived: sum of 2 quarters · filed 2023-11-01 | $36.49M derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | $12.37M 10-Q · filed 2023-11-01 | $23.54M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | $11.17M 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $37.76M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $9.53M 10-Q · filed 2022-11-01 | $19.17M derived: sum of 2 quarters · filed 2022-11-01 | $28.04M derived: sum of 3 quarters · filed 2022-11-01 | |
| 2021-06-30 | $9.64M 10-Q · filed 2022-11-01 | $18.51M derived: sum of 2 quarters · filed 2022-11-01 | ||
| 2021-03-31 | $8.88M 10-Q · filed 2022-11-01 | |||
| 2020-12-31 | $30.95M 10-K · filed 2023-02-16 | |||
| 2020-09-30 | $7.93M 10-Q · filed 2021-11-02 | $15.72M derived: sum of 2 quarters · filed 2021-11-02 | $23.01M derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | $7.80M 10-Q · filed 2021-11-02 | $15.08M derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $7.28M 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $39.28M 10-K · filed 2022-02-16 | |||
| 2019-09-30 | $9.39M 10-Q · filed 2020-10-29 | $16.29M derived: sum of 2 quarters · filed 2020-10-29 | $22.62M derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-30 | $6.90M 10-Q · filed 2020-10-29 | $13.23M derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-31 | $6.33M 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | $25.16M 10-K · filed 2021-02-12 | |||
| 2018-09-30 | $6.60M 10-Q · filed 2019-10-31 | $12.99M derived: sum of 2 quarters · filed 2019-10-31 | $18.95M derived: sum of 3 quarters · filed 2019-10-31 | |
| 2018-06-30 | $6.39M 10-Q · filed 2019-10-31 | $12.35M derived: sum of 2 quarters · filed 2019-10-31 | ||
| 2018-03-31 | $5.96M 10-Q · filed 2019-10-31 | |||
| 2017-12-31 | $23.52M 10-K · filed 2020-02-14 | |||
| 2016-12-31 | $19.89M 10-K · filed 2019-02-15 | |||
| 2015-12-31 | $19.88M 10-K · filed 2018-02-16 | |||
| 2014-12-31 | $18.10M 10-K · filed 2017-02-17 | |||
| 2013-12-31 | $16.57M 10-K · filed 2016-02-17 | |||
| 2012-12-31 | $15.86M 10-K · filed 2015-02-17 | |||
| 2011-12-31 | $15.35M 10-K · filed 2014-02-18 | |||
| 2010-12-31 | $13.07M 10-K · filed 2013-02-19 | |||
| 2009-12-31 | $11.38M 10-K · filed 2012-02-17 | |||
| 2008-12-31 | $10.23M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |